Start · Catalogue · Profile · Table
Breathing BODY HANDBOOK
Breathing · §2
Asthma AIR and MART Pathway
For decades the standard asthma kit was two inhalers: a blue "rescue" puffer for when you can't breathe, and (sometimes) a brown "preventer" you were meant to take every day. The global asthma guideline has thrown that out. One combination inhaler now does both jobs — every puff you take for relief also delivers a small anti-inflammatory dose that quietly prevents the next attack. Used as-needed for mild asthma (the AIR regimen) and daily-plus-as-needed for worse asthma (MART), the pathway roughly halves the kind of attack that ends in urgent care or a prednisone course.
Decide · Daily Evidence Strong Chapter Breathing

The wins compound: fewer middle-of-the-night coughing fits, fewer trips to urgent care, fewer prednisone courses with their weight gain and mood crash. The catch is small — you'll need a prescription, a combination inhaler costs more than the cheapest blue puffer, and you have to break the lifelong habit of reaching for that blue puffer first. The evidence is unusually solid for a chronic-disease pivot: five large independent trials and the worldwide asthma guideline all point the same way.

Asthma isn't really a spasm problem. It's an inflammation problem that causes spasms. The airways of an asthmatic are chronically irritated and swollen; the wheezing, the tight chest, the 4 AM coughing — those are downstream symptoms of a smouldering fire in the lung lining.

The blue rescue inhaler (salbutamol or albuterol — a short-acting beta-agonist, or SABA) is a bronchodilator. It pries the airways open within five minutes and lasts a few hours. What it does not do is touch the underlying fire. Use it and you feel better; the inflammation keeps going. Use it heavily and the inflammation gets worse — your airways become more reactive, not less Reddel et al. 2019.

The preventer inhaler (an inhaled corticosteroid, or ICS — budesonide, fluticasone, beclomethasone) does the opposite. It tamps down the inflammation, slowly. You don't feel anything from a single puff. You feel something six weeks in, when the attacks that should have happened didn't. That asymmetry is the whole adherence problem: the inhaler you can feel becomes the one you trust; the one that's actually keeping you alive sits unused on the shelf.

The AIR/MART pathway is a clever solution to that problem. The reliever inhaler is replaced with a combination inhaler — an inhaled steroid blended with formoterol, a long-acting bronchodilator that, unlike its cousins, kicks in within one to three minutes. Fast enough to relieve, long enough to control. Every time you reach for relief, you also get a dose of anti-inflammatory drug — automatically titrated to whatever your airways need that day GINA 2024. The behavioural and the pharmacological problem solve each other.

Does it actually work

For an evidence base in chronic disease, this one is unusually clean. Five large trials, two independent of the manufacturer, all point the same direction.

Two follow-up trials run in New Zealand, both at arm's length from the patent holder, replicated the result. Novel START found the combination inhaler cut severe attacks by half versus the blue puffer alone Beasley et al. 2019. PRACTICAL went further: in adults with mild-to-moderate asthma, the as-needed combination inhaler beat the older standard of daily preventer plus blue-puffer rescue, cutting severe attacks by roughly a third Hardy et al. 2019. That's a regimen that asks less of the patient outperforming one that asks more.

For people with worse asthma — the ones who already use a daily preventer — the MART version of this approach (the combination inhaler used both daily and on flare) has a longer evidence trail. A Cochrane review pooling 16 trials and a network meta-analysis covering nearly 17,000 patients agree: MART reduces the attacks that send you to the emergency department or onto prednisone pills by roughly a third compared with a separate daily preventer plus blue-puffer rescue Cates and Karner 2013 Sobieraj et al. 2018.

On the other side of the comparison: heavy use of the blue puffer alone is genuinely dangerous. A Swedish cohort of 365,324 asthma patients found that going through three or more blue-puffer canisters in a year — about one a month or more — was associated with a 26% higher rate of asthma attacks and a 26% higher all-cause mortality, with a clean dose-response across canister bands Nwaru et al. 2020. The same signal showed up in the 1992 New Zealand asthma-death epidemic Spitzer et al. 1992. The blue inhaler isn't safe in proportion to how much you need it; it's dangerous in proportion to how much you need it.

What staying on blue-puffer-only costs you

Picture the version of yourself who keeps treating asthma as something to manage attack by attack. The puffer goes everywhere with you. You go through a canister every six to eight weeks; the pharmacist starts to recognise you. Cold air, perfume aisles, dusty rooms, the wrong cat — each one becomes a moment of low-grade calculation about how far the next puff is.

The exercise stops first. You don't decide to stop; you just stop signing up for things that involve running. Stairs become an event. People around you start adjusting — your partner walks slightly slower without mentioning it, your friends pick the closer venue. You explain it to yourself as getting older.

The nights are the part you stop talking about. Around 3 or 4 AM, two or three times a week, you wake up coughing. You sit up, take a puff, and lie back down. It works. The next morning you're flat — the kind of tired that no amount of coffee touches, the kind that turns afternoon meetings into endurance events. The next decade of these nights is what cumulative sleep debt actually looks like.

Then the bad weeks. Twice a year, maybe three times, a cold or a smoke event triggers something the puffer can't reach. You end up on a course of prednisone pills — usually a week, sometimes more. Each course you feel: jittery, sleepless, food-craving, occasionally weepy or rage-y in ways you don't recognise. Each course you can also feel fade; the side-effect catalogue of repeated oral-steroid bursts builds up quietly in the background — bone-thinning, weight that doesn't come off, blood-sugar drift, a faint moon to the face. By age 50, four lifetime courses are enough to detectably raise your risk of osteoporosis, type 2 diabetes, cataract, and pneumonia Sullivan et al. 2018.

And in the tail of the distribution, the part nobody likes to talk about: heavy blue-puffer reliance carries a real asthma-death signal. Not a hypothetical one — a measured one, dose-dependent, across populations and decades Nwaru et al. 2020 Spitzer et al. 1992. Most heavy users will not die of asthma. The ones who do, almost always, are heavy users.

How the regimen actually works

This is a prescription change, not a supplement. You're talking to your GP or asthma nurse, not your pharmacist. The conversation is short: ask whether you can move to a combination-inhaler reliever — the GINA Track 1 pathway — and how to retire the blue puffer. Uptake of this pathway is broad but not universal; the global asthma guideline has endorsed it since 2019, the UK and most of Europe have moved with it, the US national guideline was slower and many American primary-care clinicians still default to the older two-inhaler regimen. If your doctor hasn't raised it, the question is yours to raise.

Which version of the regimen you're on depends on how active your asthma is. For mild asthma the regimen has no daily dose; for worse asthma it does.

The behavioural piece — actually retiring the blue puffer rather than letting it sit in your bag as a backup — is the part most people skip and most clinicians forget to push on. Trial data are clean because the trials enforce it; real-world results sag when patients keep the old inhaler around "just in case." If a stockpile makes you feel safer, the honest move is to hand it to the pharmacist for disposal at the same appointment you pick up the new one.

When to flag it with your doctor

What most people get wrong about the blue puffer

The deepest misconception is that the blue inhaler is the safe one and the steroid inhaler is the scary one. The evidence inverts that completely. The patient at highest risk of an attack bad enough to land them in the hospital, or in a small fraction of cases to kill them, is the patient who relies on the blue puffer and skips the preventer Nwaru et al. 2020. The relief you feel from the blue inhaler is real and immediate; the protection from the steroid is real and invisible. The felt experience pushes you toward the wrong inhaler — that's the whole game.

The second misconception is that needing the blue puffer more often means you should use it more. It's the opposite: a rising blue-puffer count is the disease getting worse, not better, and the right response is to escalate the anti-inflammatory side of treatment, not the bronchodilator side. Three canisters a year — about one a month — is the line at which population-level harm becomes measurable Nwaru et al. 2020.

Third: that as-needed combination inhaler is just "a reliever with a little steroid in it." In mild asthma, it actually beats the older standard of a daily preventer plus a blue rescue puffer — same or better attack prevention, with less total medication Hardy et al. 2019. The relabelling matters.

Where this goes wrong in practice

The regimen fails in a small number of predictable ways. None are mysterious; all are worth knowing in advance.

The stockpiled blue puffer. Most patients are reluctant to actually throw out their old reliever. It sits in a bag, a car glovebox, a bathroom drawer. When a flare hits, the hand reaches for the familiar object — and the regimen reverts to the old pattern. Trials get clean results partly because they enforce the substitution; real-world adherence sags when the substitution is left to the patient.

Poor inhaler technique. A surprisingly large fraction of asthma "treatment failure" is the drug never reaching the lungs. Pressurised metered-dose inhalers are notoriously hard to coordinate; a spacer or a dry-powder inhaler version solves it for most people. Ask to be re-checked on technique every couple of years — clinicians forget to offer.

Silent MART escalation. On the MART regimen, the as-needed component is genuinely permissive — six, eight, even twelve puffs a day is within label. But sustained daily use above about four as-needed puffs is a signal that the asthma isn't controlled, not that the regimen is working. The trap is to keep escalating quietly rather than book a review.

Under-treatment on AIR. The flip side: a small group of patients with episodic but severe asthma genuinely need a daily maintenance dose, and the as-needed-only regimen lets them under-treat between flares. If exacerbations keep happening on AIR, the answer is to move up to MART, not to keep doubling the as-needed puffs.

The upstream driver nobody treated. A well-tuned inhaler regimen can still lose to whatever is feeding the inflammation in the first place. Untreated allergic rhinitis keeps the whole airway irritated — get the nose under control and the asthma often settles with it. And hidden mould or damp at home is a trigger no inhaler will out-run; if your flares cluster indoors, that is worth hunting down before you keep escalating the dose.

The mood and cognitive cost of repeated prednisone courses. If you're still getting attacks bad enough to need oral steroids more than once a year, that itself is a sign the regimen isn't matching the disease. The pills work — but the cumulative load (weight, mood disturbance, foggy weeks, bone density, blood-sugar drift) is real and avoidable Sullivan et al. 2018. More attacks prevented is the metric; "the prednisone fixes it" is not the bar.

What changes after the switch

The first thing to notice is something you stop doing. Two or three weeks in, the 4 AM cough doesn't wake you up. You sleep through. The next morning isn't the wrecked morning. You don't remember when the night-time wheezing stopped — only that it has Beasley et al. 2019.

Around the same time, the puff count drops. The new combination inhaler doesn't go everywhere in the same paranoid way the blue one did, because flare events are getting rarer. The pharmacist stops asking how often you're refilling.

By a few months in, the stairs are just stairs again. You sign up for the run, the hike, the dance class — not because you're treating exercise as a goal but because the question of can I has quietly fallen out of the decision. People around you notice in small ways: you stop the half-step-behind, your voice doesn't catch when you're climbing, the partner who learned to walk slowly forgets to.

The year-scale signal is the absence of a thing: the bad week doesn't arrive. The cold that used to mean a prednisone course just means a cold. Across trials, severe attacks drop by roughly a half versus blue-puffer-only baselines and by about a third versus older preventer-plus-rescue regimens O'Byrne et al. 2018 Sobieraj et al. 2018. What you feel from that is, mostly, a calendar that contains the things you planned to put in it.

Over a decade, the steroid-pill side effects you would have accumulated — the weight that wouldn't come off, the moon to the face during bad seasons, the slow bone-density drift, the cataract risk, the foggy weeks — don't accumulate Sullivan et al. 2018. The anxiety background that came from never quite trusting your own lungs eases off. You stop being someone whose social plans route around their breathing.

Related to look into

A few adjacent topics that change asthma outcomes and don't fit inside the inhaler conversation:

  • Nasal breathing and mouth-tape at night. Chronic mouth-breathing dries and irritates the airways and worsens nocturnal asthma symptoms.
  • Indoor air and allergen reduction. Dust mite covers, HEPA filtration, and removing carpets matter for the allergic phenotype that drives most adult asthma.
  • Smoking and vaping cessation. The single biggest modifiable amplifier of asthma severity and a precondition for any inhaler regimen working as advertised.
  • Severe-asthma biologics. If exacerbations keep happening on MART, drugs like omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab target specific inflammatory pathways and stack on top.
  • Exercise tolerance and aerobic conditioning. Cardiovascular fitness independently lowers asthma symptom burden once the inhaler regimen is right.
Related in the handbook
Worsens / aggravates
  • — Untreated nasal allergies keep the airways inflamed — control the nose to control the asthma.
  • — If your asthma keeps flaring at home, mold and damp may be the trigger no inhaler will out-run.
  • — Scented candles in small rooms are a common, avoidable asthma trigger.
  • — Cleaning sprays, especially disinfectants, are a common asthma trigger and can even cause it.
  • — If your asthma flares at home for no clear reason, scented laundry products are a frequent hidden trigger worth dropping first.
  • — If asthma flares at home, hunt down scented products first — fragrance is a frequent, fixable trigger.
  • — New-furniture smell is VOCs and formaldehyde that can trigger asthma. Unbox elsewhere, ventilate, and run the room cool.
  • — If asthma keeps flaring, your indoor air may be a hidden trigger worth measuring and cleaning up.
  • — One overlooked indoor trigger is the daily hot shower: chloramine vapor off the water can tighten asthmatic airways.
Helps
  • — Before escalating this regimen, confirm the inhaler is actually delivering — most people use it wrong.
  • — When the inhaler pathway can't control severe asthma, a Type 2 biologic is the add-on that cuts attacks.
  • — Cleaning the air with a purifier reduces the triggers that set off asthma flares.
  • — If your asthma fires at night, your bed may be the trigger: dust mites in the sheets. Hot-wash weekly, cover mattress and pillow.
  • — Slow-breathing CO2-tolerance work reduces asthma symptom burden alongside proper inhaler treatment.
Related
  • — COPD is the other big inhaler-treated airway disease — the pathways differ, so confirm which you have.
  • — Asthma travels with other allergic conditions. Food sticking when you swallow can be EoE, the same inflammation aimed at the esophagus.
·
2